Wednesday Novo Nordisk put all their chips on the table submitting the oral version of semaglutide to the FDA using a priority voucher. If as we expect the FDA approves the drug it will set up one of the most important drug launches in the company’s history. Many analysts believe that as the first oral GLP-1 this is a slam dunk for Novo providing the blockbuster product the company desperately needs. While we believe there will be lots of interest in the drug, we aren’t yet convinced it’s a slam dunk blockbuster.
Given the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.